{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=38",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 20598,
    "total_pages": 2060,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-20T06:52:19.773Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05404750",
      "title": "Harm Reduction in HIV Primary Care for PLWH Who Use Drugs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Substance Use",
        "Stigma, Social"
      ],
      "interventions": [
        {
          "name": "Harm Reduction",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Pittsburgh",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 641,
      "start_date": "2022-04-20",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 3,
      "location_summary": "Birmingham, Alabama • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05404750"
    },
    {
      "nct_id": "NCT00542282",
      "title": "Vibration Response Imaging in Chronic Obstructive Pulmonary Disease and Asthma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease",
        "Asthma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Deep Breeze",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 75,
      "start_date": "2006-11",
      "completion_date": "2007-08",
      "has_results": false,
      "last_update_posted_date": "2009-06-16",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00542282"
    },
    {
      "nct_id": "NCT06786520",
      "title": "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CAB LA",
          "type": "DRUG"
        },
        {
          "name": "CAB ULA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2025-01-17",
      "completion_date": "2027-11-08",
      "has_results": false,
      "last_update_posted_date": "2025-06-19",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 3,
      "location_summary": "Mobile, Alabama • Coral Gables, Florida • Oak Brook, Illinois",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Oak Brook",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06786520"
    },
    {
      "nct_id": "NCT01105923",
      "title": "Study of an Intervention to Improve Problem List Accuracy and Use",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Attention Deficit Disorder With Hyperactivity",
        "Asthma",
        "COPD",
        "Breast Cancer",
        "Coronary Artery Disease",
        "Congestive Heart Failure",
        "Diabetes",
        "Glaucoma",
        "Hemophilia",
        "Hypertension",
        "Hyperthyroidism",
        "Hypothyroidism",
        "Myasthenia Gravis",
        "Osteoporosis",
        "Osteopenia",
        "Renal Failure",
        "Renal Insufficiency",
        "Sickle Cell Disease",
        "Stroke"
      ],
      "interventions": [
        {
          "name": "MAPLE",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2010-05",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2015-02-02",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01105923"
    },
    {
      "nct_id": "NCT00659659",
      "title": "A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "MEDI-563",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comp.",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2008-01",
      "completion_date": "2011-03",
      "has_results": false,
      "last_update_posted_date": "2012-10-10",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 6,
      "location_summary": "Denver, Colorado • Pittsburgh, Pennsylvania • Galveston, Texas + 2 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00659659"
    },
    {
      "nct_id": "NCT00262080",
      "title": "Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema (HAE)"
      ],
      "interventions": [
        {
          "name": "ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Phosphate Buffer Saline (PBS),",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2005-12-31",
      "completion_date": "2007-02-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 1,
      "location_summary": "Wheaton, Maryland",
      "locations": [
        {
          "city": "Wheaton",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262080"
    },
    {
      "nct_id": "NCT01353079",
      "title": "Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Allergy"
      ],
      "interventions": [
        {
          "name": "Short Ragweed Pollen Allergenic Extract",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Greer Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 429,
      "start_date": "2011-04",
      "completion_date": "2012-04",
      "has_results": true,
      "last_update_posted_date": "2015-02-05",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 1,
      "location_summary": "Warrenton, Virginia",
      "locations": [
        {
          "city": "Warrenton",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01353079"
    },
    {
      "nct_id": "NCT04988555",
      "title": "A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid, Acute",
        "Leukemia, Lymphocytic, Acute",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Enzomenib",
          "type": "DRUG"
        },
        {
          "name": "azoles",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine (AZA)",
          "type": "DRUG"
        },
        {
          "name": "Intensive chemotherapy with 7 + 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 606,
      "start_date": "2022-02-28",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-24",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 33,
      "location_summary": "Newport Beach, California • Palo Alto, California • Denver, Colorado + 24 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04988555"
    },
    {
      "nct_id": "NCT00538915",
      "title": "Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency Disorders (PIDD)"
      ],
      "interventions": [
        {
          "name": "Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ADMA Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "6 Years to 75 Years"
      },
      "enrollment_count": 63,
      "start_date": "2007-09",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2021-07-30",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "North Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538915"
    },
    {
      "nct_id": "NCT07220915",
      "title": "Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypogammaglobulinemia",
        "Autoimmune Conditions",
        "Rheumatic Conditions",
        "Infections"
      ],
      "interventions": [
        {
          "name": "Panzyga, 10% Intravenous Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 360,
      "start_date": "2026-06-10",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-20T06:52:19.773Z",
      "location_count": 6,
      "location_summary": "Glendale, Arizona • Mesa, Arizona • Scottsdale, Arizona + 3 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07220915"
    }
  ]
}